Serum tumor markers for response prediction and monitoring of advanced lung cancer: A review focusing on immunotherapy and targeted therapies.

Q3 Biochemistry, Genetics and Molecular Biology Tumor Biology Pub Date : 2024-01-01 DOI:10.3233/TUB-220039

Michel van den Heuvel, Stefan Holdenrieder, Milou Schuurbiers, Daniel Cigoianu, Inga Trulson, Huub van Rossum, David Lang

{"title":"Serum tumor markers for response prediction and monitoring of advanced lung cancer: A review focusing on immunotherapy and targeted therapies.","authors":"Michel van den Heuvel, Stefan Holdenrieder, Milou Schuurbiers, Daniel Cigoianu, Inga Trulson, Huub van Rossum, David Lang","doi":"10.3233/TUB-220039","DOIUrl":null,"url":null,"abstract":"Background: The value of serum tumor markers (STMs) in the current therapeutic landscape of lung cancer is unclear.Objective: This scoping review gathered evidence of the predictive, prognostic, and monitoring value of STMs for patients with advanced lung cancer receiving immunotherapy (IT) or targeted therapy (TT).Methods: Literature searches were conducted (cut-off: May 2022) using PubMed and Cochrane CENTRAL databases. Medical professionals advised on the search strategies.Results: Study heterogeneity limited the evidence and inferences from the 36 publications reviewed. While increased baseline levels of serum cytokeratin 19 fragment antigen (CYFRA21-1) and carcinoembryonic antigen (CEA) may predict IT response, results for TT were less clear. For monitoring IT-treated patients, STM panels (including CYFRA21-1, CEA, and neuron-specific enolase) may surpass the power of single analyses to predict non-response. CYFRA21-1 measurement could aid in monitoring TT-treated patients, but the value of CEA in this context requires further investigation. Overall, baseline and dynamic changes in individual or combined STM levels have potential utility to predict treatment outcome and for monitoring of patients with advanced lung cancer.Conclusions: In advanced lung cancer, STMs provide additional relevant clinical information by predicting treatment outcome, but further standardization and validation is warranted.","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":"S233-S268"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumor Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/TUB-220039","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The value of serum tumor markers (STMs) in the current therapeutic landscape of lung cancer is unclear.

Objective: This scoping review gathered evidence of the predictive, prognostic, and monitoring value of STMs for patients with advanced lung cancer receiving immunotherapy (IT) or targeted therapy (TT).

Methods: Literature searches were conducted (cut-off: May 2022) using PubMed and Cochrane CENTRAL databases. Medical professionals advised on the search strategies.

Results: Study heterogeneity limited the evidence and inferences from the 36 publications reviewed. While increased baseline levels of serum cytokeratin 19 fragment antigen (CYFRA21-1) and carcinoembryonic antigen (CEA) may predict IT response, results for TT were less clear. For monitoring IT-treated patients, STM panels (including CYFRA21-1, CEA, and neuron-specific enolase) may surpass the power of single analyses to predict non-response. CYFRA21-1 measurement could aid in monitoring TT-treated patients, but the value of CEA in this context requires further investigation. Overall, baseline and dynamic changes in individual or combined STM levels have potential utility to predict treatment outcome and for monitoring of patients with advanced lung cancer.

Conclusions: In advanced lung cancer, STMs provide additional relevant clinical information by predicting treatment outcome, but further standardization and validation is warranted.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

用于晚期肺癌反应预测和监测的血清肿瘤标志物：以免疫疗法和靶向疗法为重点的综述。

背景：血清肿瘤标志物（STMs）在当前肺癌治疗中的价值尚不明确：血清肿瘤标志物（STMs）在当前肺癌治疗中的价值尚不明确：本范围综述收集了有关血清肿瘤标志物对接受免疫疗法（IT）或靶向疗法（TT）的晚期肺癌患者的预测、预后和监测价值的证据：使用 PubMed 和 Cochrane CENTRAL 数据库进行文献检索（截止日期：2022 年 5 月）。医学专家对检索策略提出了建议：研究的异质性限制了所查阅的 36 篇文献的证据和推论。虽然血清细胞角蛋白19片段抗原（CYFRA21-1）和癌胚抗原（CEA）基线水平的升高可预测IT反应，但TT的结果不太明确。在监测接受 IT 治疗的患者时，STM 面板（包括 CYFRA21-1、CEA 和神经元特异性烯醇化酶）可能会超过单一分析预测无应答的能力。CYFRA21-1 测量有助于监测 TT 治疗患者，但 CEA 在这方面的价值还需要进一步研究。总之，单个或组合 STM 水平的基线和动态变化可能有助于预测治疗结果和监测晚期肺癌患者：在晚期肺癌患者中，STM可通过预测治疗结果提供额外的相关临床信息，但还需要进一步的标准化和验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Tumor Biology 医学-肿瘤学

CiteScore

5.40

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： Tumor Biology is a peer reviewed, international journal providing an open access forum for experimental and clinical cancer research. Tumor Biology covers all aspects of tumor markers, molecular biomarkers, tumor targeting, and mechanisms of tumor development and progression. Specific topics of interest include, but are not limited to: Pathway analyses, Non-coding RNAs, Circulating tumor cells, Liquid biopsies, Exosomes, Epigenetics, Cancer stem cells, Tumor immunology and immunotherapy, Tumor microenvironment, Targeted therapies, Therapy resistance Cancer genetics, Cancer risk screening. Studies in other areas of basic, clinical and translational cancer research are also considered in order to promote connections and discoveries across different disciplines. The journal publishes original articles, reviews, commentaries and guidelines on tumor marker use. All submissions are subject to rigorous peer review and are selected on the basis of whether the research is sound and deserves publication. Tumor Biology is the Official Journal of the International Society of Oncology and BioMarkers (ISOBM).